Biktarvy, confirmation of the effect of long-term investigation for 5 years of initial treatment
Biktarvy product photo Five-year long-term data of the HIV-1 drug Biktarvy (ingredient name bictegravir/emtricitabine/tenofovir alafenamide, B/F/TAF) was added to the approval requirements. Gilead Sciences Korea announced on the 27th that the Ministry of Food and Drug Safety on January 30th added clinical information on 5-year long-term data conducted on adults infected with HIV-1 after initial … Read more